New drug SAL0140 aims to slow kidney disease in major trial
NCT ID NCT07647133
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether the drug SAL0140 can reduce protein in the urine, a sign of kidney damage, in 249 adults with chronic kidney disease. Participants will receive either SAL0140 or a placebo for 16 weeks. The goal is to see if the drug can help control the disease and protect kidney function.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SAL0140
- What this could lead to
- If successful, this could point toward a new treatment to slow kidney damage in chronic kidney disease patients.
- What could go wrong
- This is an early Phase 2 trial, so results may not confirm benefit. The drug could have side effects or fail to outperform placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University
Nanjing, Jiangsu, 210002, China
-
Peking University Shenzhen Hospital
Shenzhen, Guangdong, 518036, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Aging kidneys under the microscope: could a simple test predict failure?
- Could your gut bacteria hold the key to protecting your kidneys?
- Food as medicine: could cooking classes slow kidney disease?
- Could a phone app be the key to managing kidney disease?
- A new pill aims to slow kidney failure and save lives
- AI takes on kidney disease: a new model to forecast Who's at risk